2025-05-27 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY), incorporating the provided data.  The report is in English, with a focus on numerical data followed by analysis.

**Eli Lilly and Co (LLY) Stock Analysis**

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that develops and markets medicines across a range of therapeutic areas.

**1. Performance vs. S&P 500 (VOO):**

*   **Ticker:** LLY
*   **Cumulative Return (LLY):** 241.06%
*   **Cumulative Return (VOO):** 79.45%
*   **Absolute Divergence:** 161.6 (LLY outperformed VOO by this amount)
*   **Relative Divergence:** 55.5 (LLY's outperformance is in the 55.5th percentile of its historical divergence range).
*   **Divergence Range:** Max: 313.1, Min: -27.6

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period considered. The relative divergence suggests that while the outperformance is substantial, it is positioned within the historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| :----------- | :------ | :------ | :------ | :---- | :----- |
| 2015-2017  | 10.0%   | 56.3%   | -19.0%  | 0.1   | 67.5   |
| 2016-2018  | 38.0%   | 58.6%   | 20.0%   | -0.1  | 94.9   |
| 2017-2019  | 49.0%   | 58.6%   | 19.0%   | 0.3   | 110.2  |
| 2018-2020  | 51.0%   | 58.6%   | 25.0%   | 0.1   | 144.4  |
| 2019-2021  | 105.0%  | 60.6%   | 50.0%   | 0.3   | 239.8  |
| 2020-2022  | 100.0%  | 65.0%   | 94.0%   | 0.3   | 321.9  |
| 2021-2023  | 139.0%  | 65.0%   | 122.0%  | 0.3   | 518.0  |
| 2022-2024  | 156.0%  | 72.2%   | 139.0%  | 0.3   | 690.4  |
| 2023-2025  | 91.0%   | 76.8%   | 64.0%   | 0.2   | 640.7  |

**Analysis:**

*   **CAGR:**  Compounded Annual Growth Rate, which is the rate of return required for an investment to grow from its beginning balance to its ending balance.
*   **MDD(Maximum Drawdown):** MDD means maximum loss from peak to bottom during a specific period
*   **Alpha:**  The positive Alpha values consistently show that LLY has generated returns above what would be expected based on the market risk.
*   **Beta:** Beta is the tendency of an investment's returns to respond to market volatility (represented by VOO). Eli Lilly and Co (LLY) has a tendency to be less volatile than the market
*   **Cap(B):** Market Cap for the given period

The table shows a significant increase in CAGR, Alpha, and Market Cap over the years, especially from 2019 onwards. It also demonstrates high MDD indicating a large percentage drop from a peak to a trough during a specified period.

**2. Recent Price Action:**

*   **Current Price:** 713.71
*   **Previous Close:** 715.2
*   **Change:** -0.21 (-0.03%)
*   **5-Day Moving Average:** 731.196
*   **20-Day Moving Average:** 773.9823
*   **60-Day Moving Average:** 804.4771

**Analysis:** The current price is slightly down from the previous close. The stock price is below its 5-day, 20-day, and 60-day moving averages, suggesting a short-term downward trend.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 27.69 (Oversold)
*   **PPO:** -0.6644
*   **Hybrid Signal:** cash_69%_Sell 69.8% of holdings (397 shares - Caution - MRI:0.37) (Cash Ratio: 69% on 2025-05-07)
*   **20-Day Relative Divergence Change:** -0.4 (Short-term Decline)
*   **Expected Return:** 124.2% (Long-term, vs. S&P 500)

**Analysis:**

*   The MRI indicates a low-risk environment.
*   The RSI value suggests that the stock may be oversold and could potentially see a price rebound.
*   PPO is negative and suggest a downward trend.
*   The Hybrid Signal recommends reducing holdings significantly and raising a large cash position (69%), indicating a cautious outlook. This is likely influenced by the recent price decline and potential overvaluation.
*   The negative change in relative divergence over the past 20 days confirms the recent underperformance against the S&P 500.
*   The expected return is significantly high, indicating potential for long-term outperformance if the stock is bought at its current price.

**4. Recent News & Events:**

*   **2025-05-24:** Major business developments, regulatory changes, or market events affecting LLY.
*   **2025-05-23:** Analysts discussing LLY's performance in the context of industry trends and global economic factors.
*   **2025-05-26:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **2025-05-25:** Market experts highlighting both risks and opportunities, advising monitoring of news and announcements.

**Analysis:**  Recent news points to potential volatility and significant events impacting LLY. Investors should closely monitor news releases and analyst reports.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue    |
| :---------- | :--- | :--------- |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2024-04-30 | 2.49 | 8.77 B$    |
| 2025-05-01 | 2.49 | 8.77 B$    |

**Analysis:**  The earnings per share (EPS) and revenue figures show that LLY's revenue and profitability is volatile depending on quarter. The recent spike may be a good sign.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| :------------- | :-------- | :------------- |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |
| 2024-06-30   | $11.30B   | 80.80%        |
| 2024-03-31   | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
| :------------- | :-------- | :------- |
| 2025-03-31   | $15.76B   | 17.50%   |
| 2024-12-31   | $14.19B   | 31.07%   |
| 2024-09-30   | $14.24B   | 6.81%    |
| 2024-06-30   | $13.56B   | 21.88%   |
| 2024-03-31   | $12.81B   | 17.51%   |

**Analysis:** LLY demonstrates strong revenue growth and maintains high profit margins. Return on Equity (ROE) has fluctuated but remains generally positive, indicating efficient use of equity to generate profits.

**7. Overall Summary:**

Eli Lilly and Co. (LLY) has shown strong historical outperformance against the S&P 500 and high growth rates. However, recent price action suggests a short-term pullback, supported by technical indicators like RSI and moving averages. The Hybrid Signal indicates a cautious sentiment. Recent news suggests potential volatility. The company's financials remain strong with high revenue, profit margins, and ROE, but earnings can fluctuate from quarter to quarter.

**Recommendation:**

Given the recent downturn, the hybrid sell signal, and the potentially oversold conditions, a cautious approach is warranted in the short term. Monitor news and earnings releases closely. However, the strong long-term expected return may be attractive to investors with a longer time horizon. Consider a gradual accumulation strategy if you believe in the long-term growth potential of LLY.
